(Q39689655)

14 September 2017

title

Targeting neuroinflammation in Alzheimer's disease: evidence for NSAIDs and novel therapeutics (English)

1 reference

14 September 2017

0 references

1 reference

William James Deardorff

series ordinal

1

1 reference

14 September 2017

George T Grossberg

series ordinal

2

1 reference

14 September 2017

publication date

13 June 2016

1 reference

Expert Review of Neurotherapeutics: a key contribution to decision making in the treatment of neurologic and neuropsychiatric disorders

14 September 2017

published in

1 reference

14 September 2017

volume

17

1 reference

14 September 2017

issue

1

1 reference

14 September 2017

page(s)

17-32

1 reference

Anti-inflammatory drugs and Alzheimer disease.

14 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2016.1200972

Alzheimer's disease: the amyloid cascade hypothesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2016.1200972

Neuroinflammation in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2016.1200972

Integrated systems approach identifies genetic nodes and networks in late-onset Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2016.1200972

Macrophage activation and polarization: nomenclature and experimental guidelines

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2016.1200972

Microglia mediate the clearance of soluble Abeta through fluid phase macropinocytosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2016.1200972

Innate immunity in Alzheimer's disease: a complex affair

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2016.1200972

Microglial derived tumor necrosis factor-α drives Alzheimer's disease-related neuronal cell cycle events

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2016.1200972

Inflammasomes: mechanism of action, role in disease, and therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2016.1200972

The role of astrocytes in amyloid β-protein toxicity and clearance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2016.1200972

Astrocyte senescence as a component of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2016.1200972

Arthritis and anti-inflammatory agents as possible protective factors for Alzheimer's disease: a review of 17 epidemiologic studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2016.1200972

Cyclooxygenase-1 and -2 in the different stages of Alzheimer's disease pathology.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2016.1200972

Distribution of cyclooxygenase-1 and cyclooxygenase-2 mRNAs and proteins in human brain and peripheral organs

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2016.1200972

NSAIDs and Alzheimer disease: epidemiological, animal model and clinical studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2016.1200972

Cyclooxygenase-1 null mice show reduced neuroinflammation in response to beta-amyloid

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2016.1200972

Cyclooxygenase-2 inhibition improves amyloid-beta-mediated suppression of memory and synaptic plasticity

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2016.1200972

Untangling the Web: Toxic and Protective Effects of Neuroinflammation and PGE2 Signaling in Alzheimer's Disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2016.1200972

Possible mechanisms of action of NSAIDs and related compounds that modulate gamma-secretase cleavage.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2016.1200972

NSAIDs and enantiomers of flurbiprofen target gamma-secretase and lower Abeta 42 in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2016.1200972

Non-steroidal anti-inflammatory drugs have anti-amyloidogenic effects for Alzheimer's beta-amyloid fibrils in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2016.1200972

Non-steroidal anti-inflammatory drugs stimulate secretion of non-amyloidogenic precursor protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2016.1200972

PPAR-gamma agonists inhibit production of monocyte inflammatory cytokines

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2016.1200972

Peroxisome proliferator-activated receptors alpha and gamma are activated by indomethacin and other non-steroidal anti-inflammatory drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2016.1200972

Nonsteroidal anti-inflammatory drugs repress beta-secretase gene promoter activity by the activation of PPARgamma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2016.1200972

Increased NF-κB signalling up-regulates BACE1 expression and its therapeutic potential in Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2016.1200972

Effect of non-steroidal anti-inflammatory drugs on risk of Alzheimer's disease: systematic review and meta-analysis of observational studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2016.1200972

Nonsteroidal anti-inflammatory drugs for the prevention of Alzheimer's disease: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2016.1200972

Meta-analysis of nonsteroidal antiinflammatory drug use and risk of dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2016.1200972

NSAIDs for the Chemoprevention of Alzheimer’s Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2016.1200972

No advantage of A beta 42-lowering NSAIDs for prevention of Alzheimer dementia in six pooled cohort studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2016.1200972

Does NSAID use modify cognitive trajectories in the elderly? The Cache County study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2016.1200972

Nonsteroidal anti-inflammatory drugs, aspirin, and cognitive function in the Baltimore longitudinal study of aging

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2016.1200972

Anti-inflammatory agents and cognitive decline in a bi-racial population

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2016.1200972

Clinical trial of indomethacin in Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2016.1200972

No effect of one-year treatment with indomethacin on Alzheimer's disease progression: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2016.1200972

A randomized controlled study on effects of ibuprofen on cognitive progression of Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2016.1200972

Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2016.1200972

A randomized, double-blind, study of rofecoxib in patients with mild cognitive impairment

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2016.1200972

Rofecoxib: no effect on Alzheimer's disease in a 1-year, randomized, blinded, controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2016.1200972

Long-term efficacy and safety of celecoxib in Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2016.1200972

Cognitive and cerebral metabolic effects of celecoxib versus placebo in people with age-related memory loss: randomized controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2016.1200972

A double-blind, placebo-controlled trial of diclofenac/misoprostol in Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2016.1200972

Randomized pilot study of nimesulide treatment in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2016.1200972

A randomized, double-blind, placebo controlled-trial of triflusal in mild cognitive impairment: the TRIMCI study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2016.1200972

A randomized controlled trial of prednisone in Alzheimer's disease. Alzheimer's Disease Cooperative Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2016.1200972

Effect of hydroxychloroquine on progression of dementia in early Alzheimer's disease: an 18-month randomised, double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2016.1200972

Efficacy and safety of tarenflurbil in mild to moderate Alzheimer's disease: a randomised phase II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2016.1200972

Effect of tarenflurbil on cognitive decline and activities of daily living in patients with mild Alzheimer disease: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2016.1200972

Omega-3 fatty acid treatment in 174 patients with mild to moderate Alzheimer disease: OmegAD study: a randomized double-blind trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2016.1200972

Why docosahexaenoic acid and aspirin supplementation could be useful in women as a primary prevention therapy against Alzheimer's disease?

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2016.1200972

Effects of ω-3 fatty acids on cognitive performance: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2016.1200972

Docosahexaenoic acid supplementation and cognitive decline in Alzheimer disease: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2016.1200972

Naproxen and celecoxib do not prevent AD in early results from a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2016.1200972

Cognitive function over time in the Alzheimer's Disease Anti-inflammatory Prevention Trial (ADAPT): results of a randomized, controlled trial of naproxen and celecoxib

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2016.1200972

Extended results of the Alzheimer's disease anti-inflammatory prevention trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2016.1200972

Follow-up evaluation of cognitive function in the randomized Alzheimer's Disease Anti-inflammatory Prevention Trial and its Follow-up Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2016.1200972

Results of a follow-up study to the randomized Alzheimer's Disease Anti-inflammatory Prevention Trial (ADAPT).

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2016.1200972

Statins and cognition: a systematic review and meta-analysis of short- and long-term cognitive effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2016.1200972

Therapeutic potential of statins in Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2016.1200972

Semisynthesis of novel monacolin J derivatives: hypocholesterolemic and neuroprotective activities.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2016.1200972

Why did tarenflurbil fail in Alzheimer's disease?

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2016.1200972

CHF5074, a novel gamma-secretase modulator, restores hippocampal neurogenesis potential and reverses contextual memory deficit in a transgenic mouse model of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2016.1200972

CHF5074 (CSP-1103) induces microglia alternative activation in plaque-free Tg2576 mice and primary glial cultures exposed to beta-amyloid.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2016.1200972

Mechanisms underlying the rapid peroxisome proliferator-activated receptor-γ-mediated amyloid clearance and reversal of cognitive deficits in a murine model of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2016.1200972

Peroxisome proliferator-activated receptor-gamma agonists for Alzheimer's disease and amnestic mild cognitive impairment: a systematic review and meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2016.1200972

The peroxisome proliferators activated receptor-gamma agonists as therapeutics for the treatment of Alzheimer's disease and mild-to-moderate Alzheimer's disease: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2016.1200972

T3D-959: A Multi-Faceted Disease Remedial Drug Candidate for the Treatment of Alzheimer's Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2016.1200972

Pan-PPAR modulation effectively protects APP/PS1 mice from amyloid deposition and cognitive deficits

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2016.1200972

Retinoic acid isomers facilitate apolipoprotein E production and lipidation in astrocytes through the retinoid X receptor/retinoic acid receptor pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2016.1200972

ApoE-directed therapeutics rapidly clear β-amyloid and reverse deficits in AD mouse models

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2016.1200972

Double-blind, placebo-controlled, proof-of-concept trial of bexarotene Xin moderate Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2016.1200972

Resveratrol decreases the insoluble Aβ1-42 level in hippocampus and protects the integrity of the blood-brain barrier in AD rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2016.1200972

A randomized, double-blind, placebo-controlled trial of resveratrol for Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2016.1200972

Rapid improvement in verbal fluency and aphasia following perispinal etanercept in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2016.1200972

Etanercept in Alzheimer disease: A randomized, placebo-controlled, double-blind, phase 2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2016.1200972

Selective Brain-Targeted Antagonism of p38 MAPKα Reduces Hippocampal IL-1β Levels and Improves Morris Water Maze Performance in Aged Rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2016.1200972

NLRP3 is activated in Alzheimer's disease and contributes to pathology in APP/PS1 mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2016.1200972

IL-12 and IL-23 cytokines: from discovery to targeted therapies for immune-mediated inflammatory diseases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2016.1200972

Inhibition of IL-12/IL-23 signaling reduces Alzheimer's disease-like pathology and cognitive decline.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2016.1200972

Plasma multianalyte profiling in mild cognitive impairment and Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2016.1200972

Deficiency in neuronal TGF-beta signaling promotes neurodegeneration and Alzheimer's pathology

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2016.1200972

Innate Immunity Fights Alzheimer's Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2016.1200972

IL-10 alters immunoproteostasis in APP mice, increasing plaque burden and worsening cognitive behavior.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2016.1200972

PD-1 immune checkpoint blockade reduces pathology and improves memory in mouse models of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2016.1200972

Breaking immune tolerance by targeting Foxp3(+) regulatory T cells mitigates Alzheimer's disease pathology

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2016.1200972

The promise of low-dose interleukin-2 therapy for autoimmune and inflammatory diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2016.1200972

Pharmacological targeting of CSF1R inhibits microglial proliferation and prevents the progression of Alzheimer's-like pathology

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2016.1200972

NFκB-activated astroglial release of complement C3 compromises neuronal morphology and function associated with Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2016.1200972

Astrocyte-Microglia Cross Talk through Complement Activation Modulates Amyloid Pathology in Mouse Models of Alzheimer's Disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2016.1200972

The C3a receptor antagonist SB 290157 has agonist activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2016.1200972

Scanning ultrasound removes amyloid-β and restores memory in an Alzheimer's disease mouse model

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2016.1200972

TREM2 lipid sensing sustains the microglial response in an Alzheimer's disease model

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2016.1200972

Upregulation of TREM2 ameliorates neuropathology and rescues spatial cognitive impairment in a transgenic mouse model of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2016.1200972

TREM2 deficiency eliminates TREM2+ inflammatory macrophages and ameliorates pathology in Alzheimer's disease mouse models.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2016.1200972

TREM2 Overexpression has No Improvement on Neuropathology and Cognitive Impairment in Aging APPswe/PS1dE9 Mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2016.1200972

TREM2 variants: new keys to decipher Alzheimer disease pathogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2016.1200972

TREM2-mediated early microglial response limits diffusion and toxicity of amyloid plaques

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2016.1200972

TREM2 Haplodeficiency in Mice and Humans Impairs the Microglia Barrier Function Leading to Decreased Amyloid Compaction and Severe Axonal Dystrophy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2016.1200972

Alzheimer's disease risk gene CD33 inhibits microglial uptake of amyloid beta

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2016.1200972

RAGE-dependent signaling in microglia contributes to neuroinflammation, Abeta accumulation, and impaired learning/memory in a mouse model of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2016.1200972

Clinical trial of an inhibitor of RAGE-Aβ interactions in Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2016.1200972

Effect of TTP488 in patients with mild to moderate Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2016.1200972

Confounding by indication: an example of variation in the use of epidemiologic terminology

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2016.1200972

Non-steroidal anti-inflammatory drugs and Alzheimer's disease: the epidemiological evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2016.1200972

Protective effects of NSAIDs on the development of Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2016.1200972

Risk of dementia and AD with prior exposure to NSAIDs in an elderly community-based cohort.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2016.1200972

Relation of NSAIDs to incident AD, change in cognitive function, and AD pathology

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2016.1200972

NSAID use and dementia risk in the Cardiovascular Health Study: role of APOE and NSAID type

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2016.1200972

Aspirin, NSAIDs, risk of dementia, and influence of the apolipoprotein E epsilon 4 allele in an elderly population

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2016.1200972

ADCOMS: a composite clinical outcome for prodromal Alzheimer's disease trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2016.1200972

Nonsteroidal Antiinflammatory Drugs and the Risk of Alzheimer's Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2016.1200972

10.1080/14737175.2016.1200972

21 January 2018

Identifiers

DOI

1 reference

14 September 2017

1 reference